| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
BayCysLT2 is a selective and potent cysteinyl leukotriene 2 receptor (CysLT2R) antagonist. It has an IC50 of 53 nM for the CysLT2R and a Ki of 35 nM for the CysLT2R, but is essentially inactive at the CysLT1R (IC50 > 10,000 nM). This high selectivity makes it a powerful tool for specifically studying CysLT2R-mediated signaling pathways.
|
|---|---|
| ln Vitro |
BayCysLT2 potently inhibits radioligand binding of LTD4 to the CysLT2R with an IC50 of 53 nM. It also reverses the effects of LTC4 in an isolated guinea pig heart model. In a cellular model, it protects astrocytes from ischemic injury. This demonstrates its utility as a tool to probe the function of the CysLT2R in various biological systems.
|
| ln Vivo |
BayCysLT2 administration either before or after ischemia/reperfusion (I/R) attenuates myocardial infarction damage in hEC-CysLT2R mice, which overexpress the human CysLT2R in endothelial cells. In wild-type mice, BayCysLT2 injection does not affect infarction volume but significantly inhibits LTD4-induced Evans blue dye leakage in the ear vasculature. This shows that BayCysLT2 is a potent and selective antagonist in vivo.
|
| Enzyme Assay |
Standard radioligand binding assay: Membranes from cells expressing the human CysLT2 receptor are incubated with a radiolabeled ligand, typically [3H]-LTD4, in the presence of varying concentrations of BayCysLT2. After incubation, bound radioactivity is separated from free by filtration, and the remaining radioactivity on the filter is counted. The IC50 value (53 nM) is derived from the binding curve.
|
| Cell Assay |
Standard calcium mobilization assay: HEK293 cells stably expressing the human CysLT2 receptor are seeded in 96-well plates. The cells are then loaded with a calcium-sensitive fluorescent dye (e.g., Fluo-4) and incubated with BayCysLT2. After a pre-incubation period, the cells are stimulated with the agonist leukotriene D4 (LTD4), and the fluorescence signal, which corresponds to calcium levels, is monitored. The ability of BayCysLT2 to block the LTD4-induced calcium signal can be measured.
|
| Animal Protocol |
Murine myocardial ischemia/reperfusion (I/R) injury model: Humanized CysLT2R knock-in mice (hEC-CysLT2R mice) are subjected to 30 minutes of left anterior descending (LAD) coronary artery occlusion, followed by 24 hours of reperfusion. BayCysLT2 is administered intraperitoneally (IP) at a dose of 1-5 mg/kg either before or after the ischemic insult. Infarct size is then measured by TTC staining. This protocol is used to demonstrate the cardioprotective effect of CysLT2R antagonism.
|
| ADME/Pharmacokinetics |
BayCysLT2 is a selective and potent CysLT2R antagonist. It is administered intraperitoneally at 1-5 mg/kg to mice. It is expected to have good bioavailability and a half-life appropriate for the duration of the experiment. The compound is an isophthalic acid derivative, and its PK parameters are likely characterized by standard methods.
|
| Toxicity/Toxicokinetics |
No specific toxicity data was found. As a highly selective antagonist for the CysLT2R, BayCysLT2 is expected to have low off-target toxicity. On-target risks are related to the specific role of CysLT2R in physiology, which appears to be primarily related to pathological inflammation. The compound is generally well-tolerated in acute mouse models.
|
| References | |
| Additional Infomation |
BayCysLT2 is an organic nitrogen and organic oxygen compound. It is functionally associated with γ-amino acids.
BayCysLT2 (CAS: 712313-33-2) has a molecular formula of C34H39NO8 and a molecular weight of 589.7. It is a selective CysLT2 receptor antagonist with an IC50 of 53 nM. Its IUPAC name is 3-[(3-carboxycyclohexyl)carbamoyl]-4-{3-[4-(4-phenoxybutoxy)phenyl]propoxy}benzoic acid. |
| Molecular Formula |
C34H39NO8
|
|---|---|
| Molecular Weight |
589.68
|
| Exact Mass |
589.268
|
| CAS # |
712313-33-2
|
| PubChem CID |
53394034
|
| Appearance |
Typically exists as solids at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
814.2±65.0 °C at 760 mmHg
|
| Flash Point |
446.2±34.3 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.614
|
| LogP |
6.56
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
43
|
| Complexity |
853
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(O)C=1C=CC(=C(C1)C(NC2CCCC(C(O)=O)C2)=O)OCCCC=3C=CC(=CC3)OCCCCOC4=CC=CC=C4
|
| InChi Key |
GKPAULTWHHPIHX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C34H39NO8/c36-32(35-27-10-6-9-25(22-27)33(37)38)30-23-26(34(39)40)15-18-31(30)43-21-7-8-24-13-16-29(17-14-24)42-20-5-4-19-41-28-11-2-1-3-12-28/h1-3,11-18,23,25,27H,4-10,19-22H2,(H,35,36)(H,37,38)(H,39,40)
|
| Chemical Name |
3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-phenoxybutoxy)phenyl]propoxy]benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6958 mL | 8.4792 mL | 16.9584 mL | |
| 5 mM | 0.3392 mL | 1.6958 mL | 3.3917 mL | |
| 10 mM | 0.1696 mL | 0.8479 mL | 1.6958 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
